Navigation Links
Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
Date:3/7/2012

CARLSBAD, Calif., March 7, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 1 study of ISIS-STAT3Rx, a Generation 2.5 antisense drug designed to treat cancer.  ISIS-STAT3Rx specifically reduces the production of signal transducer and activator of transcription 3 (STAT3). Because STAT3 is over expressed in numerous types of cancers, ISIS-STAT3Rx has the potential to be broadly useful for both solid and liquid tumors.  The ISIS-STAT3Rx development plan is initially focused on key cancers where there is a high unmet medical need and a strong link to STAT3, such as hepatocellular carcinoma (HCC) and ovarian cancer.  Advancements in Isis' technology platform have resulted in the improved potency of Generation 2.5 antisense drugs creating opportunities for drugs like ISIS-STAT3Rx to be effective in the more difficult to treat types of cancer. 

"The role of STAT3 as a key factor critical for tumor cell growth and survival of cancer cells has made STAT3 widely viewed as an important target of interest," said David S. Hong, M.D., Assistant Professor, Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center.  "STAT3 is a well understood transcription factor involved in multiple survival mechanisms that intersect with the growth, metastasis and invasiveness of cancer. The ability to selectively inhibit STAT3 could allow us to effectively treat some of the most difficult to treat cancers."

"We and many others are very interested in STAT3 as a therapeutic target because of the important role STAT3 plays in the survival and growth of difficult to treat cancers.  The marked improvements in potency of our Generation 2.5 antisense drugs that we have seen in cancer models cause us to believe that these drugs could have a profound impact in treating cancer,"
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Initiates Plans for China Office
2. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
3. Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
4. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
6. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
7. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
8. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
9. Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
10. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
11. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... ST. LOUIS , July 22, 2014  According ... the time their children spend on digital devices. An ... the ages of 10 and 17 estimate they use ... day. However, a separate AOA survey of parents revealed ... use an electronic device for that same amount of ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... July 22, 2014 Get Real ... Immune Deficiency Foundation (IDF) to provide their ... that will allow them to electronically track their symptoms, ... their illnesses. It will also allow those patients and ... consent to have their data shared with the ...
(Date:7/22/2014)... 22, 2014 JumpSoft, Inc., a ... automated recovery at the application level, today released ... to application-centric management. , Based on ... the report provides insights, context and depth regarding ... application and system uptime. London, Ink, a B2B ...
(Date:7/22/2014)... Recently, MyDressCity.com has excitedly launched a promotion for ... all people can get a discount, up to 60% off, ... the new range; all the new items are of top ... Quinceanera gowns for worldwide clients. Our dress specialists are always ... of MyDressCity.com, “Our Quinceanera dresses are selling well in the ...
(Date:7/22/2014)... July 22, 2014 BlackBox Biometrics, Inc. ... Gauge™ System with advancements including a new ... gauges represent a functional revision of the already robust ... capture complex data on blast events by recording a ... The extreme changes in overpressure that accompany a blast ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 "The Big Secrets: ... is one of the most important books young people can read. ... It will murder some of the “truths” people have been living ... what will the new truths be? From sex to death, this ... age 16 to 21, and it tells it like it is. ...
Breaking Medicine News(10 mins):Health News:Get Real Health to Partner with Immune Deficiency Foundation 2Health News:Get Real Health to Partner with Immune Deficiency Foundation 3Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 2Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 3Health News:Beautiful Dama Dresses Now Released By Popular Online Supplier MyDressCity.com 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 3Health News:Strategic Book Publishing & Rights Agency Announces the Release of its Newest Title, “The Big Secrets: Ten Things Every Young Person Should Know About and Why” 2
... number of HIV cases in Africa as of last ... from the United Nations //.The World Health Organization has ... AIDS in Africa. ,The WHO has ... in healthcare in Africa could be used to give ...
... Science (RIMS) here is battling for life after doctors gave her ... to RIMS for a surgery, received B+ blood instead of her ... next 48 hours are critical for her. ,She was ... ago. Her condition worsened when she was given the wrong blood, ...
... replaced by a pill according to European researchers. The ... of the Grazax allergen tablet.// Hay fever and other ... ,Allergies are a result of the immune system reacting ... ,Immunotherapy is supposed to enhance tolerance of ...
... of people admitted into hospitals with diabetic related issues is ... of Health and Welfare.// ,The author of the report, ... and 2004, hospital admissions for diabetes increased by 20 per ... more people are being diagnosed with diabetes, it is increasing ...
... have found that a glass of orange juice every day ... citrus juices like lemonade. // ,The study that is ... 26 issue of the Clinical Journal of the American Society ... that all citrus fruit juices could help prevent the formation ...
... Australia are conducting a study involving 300 pairs of older ... ,'Even though we have twins that are identical, ... Sachdev said. 'By studying twins, we will be able to ... and which are environmental.' ,Prof Sachdev said that time ...
Cached Medicine News:Health News:A Glass of Orange Juice To Keep Recurrence Of Kidney Stones At Bay 2
Form should always follow function. Thats why EagleVision created the FlexPlug, the only tapered shaft punctum plug with contouring traction ribs. Designed to provide the ultimate in flexibility, fix...
The latest wave in punctum plugs! Unique design featureing reservoir indentations to reduce foreign body sensation. Elast™ - a proprietary formulated, hight performance Liquid Silicon Rubber ...
... Attain Prevail's steerable tip, along with various ... obtain the curve you need, when you ... visualization of the cardiac venous anatomy, adjust ... - Adjust curve and reach by ...
... Attain™ Deflectable Catheter - designed to be ... single catheter. Steerablility - Create a variety ... a single, steerable guide catheter. Lock the ... to address each patient's unique anatomy during ...
Medicine Products: